- ISSN 1008-5734
- CN 11-4015/R
- 1999年创刊
- 主管: 中国科学技术协会
- 主办: 中华医学会
ObjectiveTo determine the effect and influence factors of amenorrhea due to adjuvant chemotherapies of anthracycline-based and anthracycline followed by taxen in premenopausal patients with early breast cancer.MethodsCase records of the patients who were premenopausal and estrogen receptor-positive with early breast cancer and received adjuvant chemotherapies of anthracycline-based and anthracycline followed by taxen in Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College from 2008 to 2010 were collected and retrospectively analysed. The chemotherapy regimens included anthracycline-based regimen 6EC (epirubicin 75 mg/m2 and cyclophosphamide 600 mg/m2 for 6 cycles and each cycle taking 21 days ) and the anthracycline followed by taxen regimen 4EC-4T ( epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 for 4 cycles and each cycle taking 21 days, followed by paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 for 4 cycles and each cycle taking 21 days). The patients were divided into two groups by the regiments. The incidence of chemotherapy-induced amenorrhea (CIA) was calculated and the recovery situation of menses and ovarian function in the patients with CIA during two years after the end of chemotherapy was recorded. The ovarian function was showed by luteinizing hormone, follicle-stimulating hormone, and estradiol levels. Influence factors of CIA was analysed in Logistic regression and χ2 test methods. ResultsNinety-six patients were enrolled in this study. Of them, 45 patients were in the 6EC group with a media age of 43-year-old and 51 patients were in the 4EC-4T group with a media age of 42-year-old. Seventy-seven of ninety-six patients (80.2%) suffered from CIA during two years after the end of chemotherapy. Of the 77 patients with CIA, 51 patients′menses(66.2%) normalized and 53 patients′ovarian function(68.8%) normalized during the two years after the end of chemotherapy. There were no statistical differences in the CIA incidence, the rate of recovery of menses, and the rate of recovery of ovarian function between the 4EC-4T and the 6EC groups ［75.6% (34/45) vs. 84.3% (43/51), 70.6% (24/34) vs. 62.8% (27/43), 73.5% (25/34) vs. 65.1% (28/43), P>005 for all the comparisons］. Age was an important influence factor of outcome of CIA ［P=0.048, hazard ratio=0.759, 95% confidence interval (0.448, 0.968)］. The incidences of CIA and the rates of recovery of ovarian function in the patients aged >40 years and the patients aged ≤40 years were 86.9% (53/61) vs. 686% (24/35), 56.6% (30/53) vs. 100.0% (24/24) respectively,(P=0.022, P=0.000). The time of menses recovery synchronized with the time of ovarian function recovery in the patients aged ≤40 years and the time of menses recovery (a median time of 11 months) was later than the time of ovarian function recovery ( a median time of 9 months ) in the patients aged >40 years.ConclusionsBoth anthracycline-based and anthracycline followed by taxen regiments can induce CIA in the premenopausal patients with early breast cancer and the incidence and outcome of the two groups are similar. Age is an important influence factor of the incidence and outcome of CIA. The choice of endocrinotherapy after postoperation chemotherapy for the younger patients with CIA should be careful.
To compare the efficacy and safety of pemetrexed and docetaxel as second-line treatment for elderly patients with advanced non-squamous non-small-cell lung cancer(NSCLC).MethodsThe data of patients with advanced non-squamous NSCLC and ≥65 years old in Department of Thoracic Surgery, Xuanwu Hospital of Capital Medical University from January 2009 to March 2012 were collected and analyzed retrospectively. According to the chemotherapy regimens, the patients were divided into 2 groups: the pemetrexed group (intravenous infusion of pemetrexed 500 mg/m2 on the first day) and the docetaxel group (intravenous infusion of docetaxel 75 mg/m2 on the first day). Each treatment cycle consisted of 3 to 4 weeks. The objective response rate (ORR), disease control rate (DCR), and incidence of adverse reactions after 2 cycles of treatment in the 2 groups were compared.ResultsA total of 146 patients were entered in this study．Of them, 56 patients were in the pemetrexed group, including 30 men and 26 women with an average age of (69.6±4.7) years; and 90 patients were in the docetaxel group, including 62 men and 28 women with an average age of (67.9±4.5) years. There were no significant differences in pathological types, stages, and performance status scores between the 2 groups. After 2 cycles of treatment, the ORR in the pemetrexed group was higher markedly than that in the docetaxel group ［32.1% (18/56) vs. 17.8% (16/90)，P=0.046］. The differences of the DCR in the pemetrexed and the docetaxel groups were not statistically significant ［73.2% (41/56) vs. 77.8% (16/90), P=0.530］. Neutropenia, thrombocy-topenia, anemia, nausea and vomiting, neurotoxicity, alopecia, and ther adverse drug reactions occurred in the 2 groups. The incidence of Ⅲ-Ⅳ levels of eutropenia and alopecia and Ⅰ-Ⅱ levels of neurotoxicity in the pemetrexed group were lower significantly than those in the docetaxel group ［7.1% (4/56) vs. 27.8% (25/90), P=0.001; 21.4% (12/56) vs.52.2% (47/90), P=0.000; 17.9% (10/56) vs. 33.3% (30/90), P=0.04)］. There were no occurrence of renal function impairment and chemo treatment-related death in the 2 groups. ConclusionPe-metrexed and docetaxel are both effective in the treatment for elderly patients with advanced non-squamous NSCLC, but pemetrexed is safer than docetaxel.
To evaluate the efficacy and safety of pretransplant conditioning regimens with intravenous (IV) infusion of busulfan once daily and cyclophosphamide in patients undergoing allogeneic stem cell transplantation allo -HSCT. MethodsThe data of consecutive patients treated with a conditioning regimen with busulfan and cyclophosphamide (Bu/Cy) before undergoing allo-HSCT in Xuanwu Hospital of Capital Medical University from January 2004 to June 2012 were collected and retrospectively analyzed. All patients were divided into the oral group ［the inpatients were treated with oral Bu 4.0 mg/(kg·d) for 3 days from January 2004 to June 2006］ and the IV infusion group ［the inpatients were treated with IV infusion of Bu 3.2 mg/(kg·d) for 3 days from July 2006 to June 2012］. The incidence of adverse reactions, the situation of hematopoietic reconstitution, and survival rate in the two groups were recorded.ResultsA total of 50 patients were collected. Of them, 34 patients were in the IV infusion group and 16 patients were in the oral group. There was no significance differences in gender, age, and numbers of transplanted stem cells between the two groups (P>0.05). The incidence of oral mucositis, gastrointestinal reactions, and liver damage in the IV infusion group were lower than those in the oral group ［11.7% (4/34) vs. 43.8% (7/16), 17.6% (6/34) vs. 50.0% (8/16), 20.6%(7/34) vs. 50.0% (8/16), respectively, all P<0.05］ Adverse reactions such as hepatic veno-occlusive disease or epilepsy were not found. The hematopoietic reconstitutions were achieved in all patients in the two groups. The time that peripheral blood neutrophil count ≥0.5×109/L and platelet count ≥20×109/L required were (14.3±3.5)d and (15.6±4.0)d, (17.5±5.0)d and (19.0±6.7)d in the IV infusion and the oral groups, respectively. There were no differences between the two groups (P>0.05). The 5-year survival rates were (69.5±12.1)% and (62.5±12.1)% in the IV infusion and the oral groups, respectively. There were no differences between the two groups (P>0.05). ConclusionPretransplant conditioning regimen with IV infusion of busulfan once daily and cyclophosphamide in patients with hematological malignancies and undergoing allogeneic stem cell transplantation is safer than that with oral busulfan and its efficacy is clear.
ObjectiveTo explore the correlation between UDP-glucuronosyltransferases 1 family polypeptide A(UGT1A)gene polymorphism and the adverse reactions induced by antineoplastic agent irinotecan, in order to provide a reference of individual therapy for patients with tumor.MethodsThe subjects were 233 healthy volunteers and 196 patients with tumor received irinotecan. The healthy volunteers comprised 169 male and 64 female with mean age of (25±5) years. Of the 196 patients with tumor, 92 had carcinoma of rectum, 45 had cervical carcinoma, and 59 had epithelial ovarian cancer. They comprised 54 male and 142 female with a mean age of (61±19) years. The gene polymorphism of UGT1A1*6, UGT1A1*28, UGT1A3*1, UGT1A3*2, UGT1A3*3, UGT1A3*4, and UGT1A9*22 were detected by pyrosequencing. The genotypic mutation frequency of UGT1A in subjects between the 2 groups were compared. The incidences of delayed diarrhea and neutropenia in patients with different UGT1A genotypes were compared. The risk factors of adverse reactions due to irinotecan were analyzed by Logistic regression analysis. The results were represented by odds ratio (OR) and 95% confidence interval (CI).ResultsThe UGT1A3*2 genotypic mutation frequency in the patients with tumor was significantly lower than that in the healthy volunteers (50.3% vs. 68.5%, P=0.014), and the UGT1A3 * 3 genotypic mutation frequency in the patients with tumor was significantly higher than that in the healthy volunteers (26.0% vs. 6.2%, P=0.001). The incidences of level Ⅱ-Ⅳ and Ⅲ-Ⅳdelayed diarrhea, and the neutropenia were 48.5% (95 cases), 11.2% (22 cases), and 49.0% (96 cases) in 196 patients with tumor, respectively. The incidences of level Ⅱ-Ⅳ and Ⅲ -Ⅳ delayed diarrhea in UGT1A1*28 wild type (WW) carriers were significantly lower than those in the mutant heterozygote (WM)+homozygous mutant (MM) genotype carriers ［Ⅱ-Ⅳ: 40.4%(57/141)vs. 69.1%(38/55)，P=0.006；Ⅲ-Ⅳ: 5.7%(8/141) vs. 25.5%(14/55)，P=0.001］. The incidences of level Ⅱ-Ⅳdelayed diarrhea in UGT1A9*22 (WW) carriers were significantly lower than those in the WM and MM carriers ［26.2%(17/65)vs. 47.6%(40/84)，P=0.006；26.2%(17/65)vs. 51.1%(24/47)P=0.0057］. There were no statistical differences in incidences of level Ⅲ-Ⅳ neutropenia among the patients with different genotypes. Logistic regression analysis showed that UGT1A genotype was related to the delayed diarrhea(OR=5.657，95%CI: 4.782-7.245，P=0.039). ConclusionUGT1A1* 28 and UGT1A9* 22 gene polymorphism may increase the risk of delayed diarrhea induced by irinotecan.
ObjectiveTo understand the changes in cyclosporine A (CsA) blood concentration, the occurrence of rejection and adverse reactions in patients after heart transplantation (HT), and to explore their correlations.MethodsThe clinical data of patients who underwent HT in Beijing Anzhen Hospital from January 2010 to December 2011 were collected and analyzed retrospectively. The patients′general condition, monitoring situation of CsA blood concentration, as well as the occurrence of rejection and adverse reactions were recorded. The relationship between CsA trough concentration (C0), peak concentration (C2), and rejection, adverse reactions were analyzed.ResultsTwenty-seven patients were enrolled in the analysis. They comprised 24 males and 3 females with a mean age of (38±14) years, a mean height of (170±10) cm, a mean body weight of (68.0±15.8) kg. Primary diseases included 18 cases with dilated heart disease, 4 cases with coronary atherosclerotic cardiopathy, 3 cases with valvular cardiomyopathy, one case with arrhythmogenic right ventricular cardiomyopathy, and one case with noncompaction of ventricular myocardium. The CsA blood concentration was low in early postoperative phase(＜1 month). Of the 75 C0 tests, the levels of C0 in 35 tests (46.7%) were below the range of effective concentration. Of the 69 C2 tests, the levels of C0 in 56 tests (81.2%) were below the range of effective concentration. C0 increased from 1 to 3 months after HT, decreased gradually 4 months after HT, and tended to be stable 7 months after HT. C2 increased from 1 to 3 months after HT, decreased gradually 4 months after HT, and increased slightly 13 months after HT. Rejection occurred in 9 of the 27 patients (33.3%), in 8 cases acute rejection occurred 4 to 12 months after HT. The main clinical manifestations were fatigue, loss of appetite, and palpitation after exercise and irritability. One patient died. In one case chronic rejection occurred 13 months after HT, the clinical manifestations included increased heart rate and peripheral blood lymphocyte count. Seven of the 27 patients (25.9%) developed renal injury. The main clinical manifestations were decline in creatinine clearance, rise in serum urea, creatinine and potassium, and hyperuricemia. The renal injury occurred in 3, 2, and 2 patients within 1 month, 3 to 6 months and 7 to 12 months after HT, respectively. One patient (3.7%) developed liver injury 2 months after HT, the clinical manifestations were increased levels of alanine aminotransferase (ALT) and total bilirubin (TBil).The levels of total cholesterol, LDL-cholesterol, and triglycerides increased in 18 patients (66.7%), occurred in 17 and 1 patients within 3 months and 7 to 12 months after HT, respectively. The levels of fasting plasma glucose increased in 10 patients (37.0%) and occurred in 7, 2 and 1 patients within one month, 4 to 12 months, and 18 months after HT, respectively. C0 and C2 in patients with non-rejection were significantly higher than those with acute rejection ［(216±90) μg/L vs. (167±103) μg/L, (718±297) μg/L vs. (472±251 ) μg/L, all P<0.01］. C0 and C2 in patients with adverse reactions were significantly higher than those without adverse reactions ［(241±93) μg/L vs. (190±95) μg/L, (837±314) μg/L vs. (596±283) μg/L, all P<0.01］. C0 was related to the blood serum urea, the creatinine, and the fasting plasma glucose (r=0.359, P=0.000; r=0.170, P=0.014; r=0.164, P=0.018). C0 and C2 were related to the TBil,TC, and LDL-C (r=0.182, P=0.009; r=-0.170, P=0.018; r=0.267, P=0.001; r=0.320, P=0.000; r=0.251, P=0.001; r=0.275, P=0.000). ConclusionsThe CsA blood concentration in patient after HT is closely related to the occurrence of rejection and adverse reactions. Monitoring of CsA blood concentration is helpful to adjust the dose of CsA timely in order to reduce the incidence of rejection and adverse reactions.
ObjectiveTo explore the occurrence and related factors of blood coagulation dysfunction due to cefoperazone sodium and sulbactam sodium in neonates.MethodsCase records of the neonates who developed blood coagulation dysfunction due to cefoperazone sodium and sulbactam sodium for injection (ADR group) in Zaozhuang Municipal Hospital of Shandong Province from May 2007 to April 2012 were collected and retrospectively analysed. The general situation, the situation of drug use, clinical symptoms, laboratory examinations ［activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), and fibrinogen (FIB)］, and clinical outcomes of the neonates were recorded. The results of coagulation function tests of normal neonates for the control (the normal control group) were obtained from a literature. Related factors of adverse reactions were analysed in Logistic regression.ResultsThere were 36 neonates (19 males and 17 females) in the ADR group, which accounted for 4.7% of 768 neonates. There were 32 neonates (25 males and 7 females) in the control group. The values of APTT, PT, and TT in the ADR group were longer markedly than those in the control group ［(50.3±14.4) s vs. (42.5±6.4) s，P＜0.05; (16.2±3.9) s vs. (13.4±2.6) s, P＜0.01; (21.2±4.5) s vs. (16.3±3.7) s，P＜0.01］. The FIB level was lower markedly than that in the ontrol group ［(1.7±0.4) g/L vs. (2.0±0.6) g/L, P<0.05］. Gestational age <34 weeks, weighing <2000 g, and birth asphyxia history were risk factors of blood coagulation dysfunction induced by sodium cefoperazone sodium and sulbactam. After the drug withdrawal, vitamin K1 and other supportive treatments were given, the blood coagulation function of 34 neonates (94.4%) returned to normal within 7 days and 2 neonates (5.6%) died of deterioration of their primary diseases.ConclusionThe incidence of neonates′blood coagulation dysfunction induced by sodium cefoperazone sodium and sulbactam is 4.7% and risk factors are preterm birth, low weight, and history of asphyxia.
Hepatitis B virus (HBV) in a dormant or latent state in patients with cancer may be reactivated when the patients receive antineoplastic combined chemotherapy protocols or immunosuppressive agents therapy. Then, the patients develop symptoms of hepatitis, accompanied by HBV DNA levels exceeding more than 10 times of basic level or absolute HBV DNA levels >20,000 IU/ml. Due to HBV reactivation, 4.5%-8.1% patients dead from liver disease and 23.3%-71.0% of patients′chemotherapy program have to be discontinued or changed. The mechanism of HBV reactivation may be that antineoplastic agents and immunosuppressive agents suppress the function of T cells and natural killer cells and massive viral replication is induced subsequently. The HBV reactivation in cancer patients is in relation to the stages of HBV infection, the type of malignancy, and the chemotherapy protocols. Lamivudine and other nucleos(t)ide analogues could be used to prevent and treat effectively HBV reactivation in cancer patients. Patients with cancer should be screened for HBV infection before receiving chemotherapy. A preventive use of nucleos(t)ide analogues is effective to decrease the incidence and severity of HBV reactivation in high-risk patients.
A 37-year-old male underwent the synchronal radiochemotherapy combined with nimotuzumab for stageⅢ nasopharyngeal carcinoma. He received an IV infusion of nimotuzumab 200 mg dissoloved in 0.9% sodium chloride 250 ml on the first, sixth, forty-first, and forty-eighth days, respectively. The intensity-modulated radiation therapy was given from the sixth day to the fifty-first day. Two cycles of the synchronal chemotherapy ［an IV infusion of cisplatin 80 mg/(m2·2 d), 3 weeks for a cycle］ were given from the twenty-eighth day.The patient reported anosphrasia on the second day after the first IV infusion of nimotuzumab. The symptom of insensitivity to all kinds of smell lasted till the fifty-seventh day when the patient′s condition was improved and he was discharged. The patient reported that he could smell pungent smell one month after discharge for subsequent visit and his olfactory sensation was partly restored on six month′s subsequent visit.
A 57-year-old male patient with pancreatic cancer received postoperative chemotherapy with an IV infusion of gemcitabine 1.6 g on days 1 and 8 combined with 3 capsules of tegafur, gimeracil and oteracil potassium orally (each capsule contains tegafur 20 mg, gimeracil 5.8 mg, and oteracil potassium 19.6 mg) twice daily on days 1-14 and one cycle took 21 days. On day 3 of drug use, the patient developed generalized burning pain and his highest temperature reached 39.6 ℃. Sporadic prunosus pruritus appeared in his limbs, chest, and back. Tegafur, gimeracil and oteracil potassium capsules were stopped immediately and gemcitabine was continued. On day 5 of drug use, the inside of his limbs, chest, and back were covered a large area of erythema multiforme, of which experienced vesicular in the center, red bulla fusing into lamella, and rupture and wound exposure, accompanied by erosive oral mucosa at the same time. Symptomatic treatments were given and, two weeks later, the rashes basically subsided. One week later, he received two cycles of combination chemotherapy with gemcitabine and fluorouracil and two cycles of capecitabine for chemotherapy as well and the rashes did not recur.
A 56-year-old man received a radiotherapy plus cetuximab molecular targeted therapy for nasopharyngeal carcinoma. He received an IV infusion of cetuximab 600 mg first time, and then 400 mg once a week. Eleven days after the first medication, red macules and pustules appeared on his face, chest and back. His oral mucosa was red and swollen at the same time. Loratadine and furancilin solution were given for anti-allergic treatment and gargle. The dose of cetuximab decreased to 300 mg on the 4th medication, but the symptoms were not improved. He developed ulcers in mouth, map-like changes in corpora linguae, and skin erosion in neck. A gargle with sodium hydrocarbonate solution and anti-infective therapy were given. Cetuximab was withdrawn after 6 times of medication. About 6 weeks after drug withdrawl, the patient′s injuries in his skin and oral mucosal were improved.
Two male patients, aged 17 and 36 years old, took amoxicillin 0.5 g for upper respiratory tract infection. Erythema appeared on their trunk about four hours after taking the third dose in patient 1 and about six hours after taking the first dose in patient 2, respectively, and then spread to their whole body, accompanied by fever. Acute generalized exanthematous pustulosis was diagnosed. Anti-inflammatory and anti-allergy treatments were given. Five days later, the erythema and pustules basically subsided.
A 55-year-old female patient received an IV infusion of docetaxel 140 mg for lymph nodes, bones, and liver metastases after operation of breast cancer. In the morning of day 6 after chemotherapy, she developed a lot of fresh blood in her stool. Her heart rate was 120 beats/min. Her routine blood tests showed the following levels: white blood cell count 0.9×109/L, hemoglobin 103 g/L, platelet count 62×109/L. She received an IV injection of hemocoagulase 2 U and an IV infusion of aminomethylbenzoic acid 0.2 g immediately. In the noon of the same day, a lot of fresh blood appeared in the patient′s stool again and she felt palpitation and fatigue. Routine blood tests showed a white blood cell count of 0.5×109/L, a hemoglobin level of 75 g/L, and a platelet count of 52×109/L. She received enema with Yunnanbaiyao(云南白药)1 g+lyophilized thrombin powder 4000 U+iced saline 100 ml every 2 h; continuous IV infusion of somatostatin 3 mg for 12 h; transfusion of suspended red blood cells 2 U and apheresis platelets 1 U. The electron colonoscopy scanning showed multiple rectal ulcers with one site of bleeding. Then endoscopic hemostasis was performed, and no bleeding recurred.
A 57-year-old woman, who had 20 years history of hypertension, was treated with long-term use of oral aspirin, nifedipine, and bisoprolol fumarate. Oral clopidogrel hydrogen sulfate 75 mg once daily and an IV infusion of cinepazide maleate 320 mg once daily were added to her regimen due to angina pectoris caused by coronary atherosclerotic heart disease. Six hours later, the patient developed intermittent hematuria, followed by urinary frequency, urinary urgency, and urodynia. Routine urine test showed occult blood (+++) and 17 red blood cells/HP. Ultrasonography showed no abnormal changes in bilateral kidney and bladder. Clopidogrel hydrogen sulfate was withdrawn. The next day, her urine color was normalized gradually and routine urinalysis showed occult blood (++) and 4 red blood cells/HP. Three days later, all results in the routine urine test was within normal range.
Three patients with severe liver diseases and infections(all males, aged 40, 68, and 50, respectively)were treated with carbapenem, linezolid, and fluconazole. No obvious change of hemogram result was found during the period of drugs use. The therapy was replaced with an IV infusion of piperacillin sodium and tazobactam sodium 4.5 g every 8 hours due to poor efficacy. Patient 1 developed platelet count decrease and anemia after the treatment with piperacillin sodium and tazobactam sodium for 11 days. Patients 2 and 3 developed platelet count decrease and exacerbation of anemia after the treatment with piperacillin sodium and tazobactam sodium for 4 and 7 days, respectively. Three patients′ hemoglobin levels and plateletcounts apparently recovered on days 31, 21, and 7 after the discontinuation of medication, respectively.
A 70-year-old woman received oral carbamazepine for epilepsy. Two weeks later, the treatment was switched to gabapentin 300 mg once daily on the first day followed by 300 mg twice daily due to poor efficacy. One month later, she presented with upper abdominal pain after eating barbecue food. Laboratory tests revealed the following levels: alanine aminotransferase (ALT) 403 U/L, aspartate aminotransferase (AST) 740 U/L, lactate dehydrogenase (LDH) 601 U/L, alkaline phosphatase (ALP) 161 U/L, and γ-glutamyl transferase (γ-GT) 295 U/L. Gabapentin was stopped and liver protective treatment was given. One week later, repeat liver function tests showed the following levels: ALT 38 U/L, AST 19 U/L, LDH 143 U/L, ALP 146 U/L, and γ-GT 134 U/L.
A 69-year -old woman was hospitalized because of repeated cough and cough up phlegm for 4 months and fatigue for one month. The electrolyte analysis revealed a potassium level of 2.4 mmol/L and an electrocardiogram showed flat T waves, fusion of T and U waves, and the heart rate-corrected QT (QTc) interval of 468 ms. Hypokalemia was diagnosed. Potassium supplement treatment was given. However, the potassium level was 3.2-3.3 mmol/L after 2 days of treatment. A careful history taking revealed that the patient had been taking compound licorice tablets by herself for cough for more than 2 months (a total of more than 500 tablets). The compound licorice tablets were stopped and potassium supplement was given continuously. The next day, the patient′s potassium level increased to 4.4 mmol/L and her fatigue relieved. An electrocardiogram showed normalization of T waves and QTc interval. After 3 days of discontinuation of compound licorice tablets, the potassium supplement treatment was stopped. The patient′s potassium level remained 3.6-3.9 mmol/L. Abnormal potassium level did not recur during the 3 months of follow-up.
A 59-year-old women received 2 capsules of Xuezhitong capsules three times daily due to hyperlipoidemia. Before treatment laboratory test showed the following values: total cholesterol 8.43 mmol/L, triglycerides 3.86 mmol/L, LDL cholesterol 5.28 mmol/L, alanine amino-transferase 37 U/L, aspartate aminotransferase 33 U/L,γ-glutamylacyl transferase (γ-GT) 46 U/L, and total bilirubin 10.9 μmol/L. Four weeks after receiving Xuezhitong capsules, the parameters of serum lipid were improved but γ-GT values increased to 166 U/L. Xuezhitong capsules were stopped. γ-GT values decreased to 86 U/L 2 months later and 59 U/L 3 months later. The patient self-medicated with Xuezhitong capsules again for 4 weeks and then the drug was withdrawn. Liver function test revealed γ-GT 159 U/L. Two months later γ-GT decreased to 92 U/L.
京期出证字第1068号
京ICP备13016081号-2
Copyright © Adverse Drug Reactions Journal
